Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | MMP1 | P03956 | 1/20 | 0.62 |
| ▸ | GBA1 | P04062 | 1/20 | 0.62 |
| ▸ | P4HB | P07237 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25191023 | 0.88 | MAPT (0.77) | MAPTMAOAMAOBPOLBRAB9A | |
| SCHEMBL25193872 | 0.86 | NFE2L2 (0.78) | NFE2L2MAPTMAOAMAOBPOLB | |
| SCHEMBL25196428 | 0.86 | NFE2L2 (0.78) | NFE2L2MAPTMAOAMAOBPOLB | |
| SCHEMBL981712 | 0.86 | NFE2L2 (1.00) | NFE2L2MAPTRAB9ACYP3A4CYP2C19 | |
| SCHEMBL981711 | 0.86 | NFE2L2 (1.00) | NFE2L2MAPTRAB9ACYP3A4CYP2C19 | |
| SCHEMBL25223568 | 0.85 | NFE2L2 (0.67) | NFE2L2MAPTMAOBNFKB1MEN1 | |
| SCHEMBL25223567 | 0.85 | NFE2L2 (0.67) | NFE2L2MAPTMAOBNFKB1MEN1 | |
| SCHEMBL815315 | 0.84 | NFE2L2 (0.70) | NFE2L2CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL25194532 | 0.84 | NFE2L2 (0.74) | NFE2L2MAOAMAOBMMP1MMP2 | |
| SCHEMBL4694196 | 0.84 | NFE2L2 (0.69) | NFE2L2MAPTMAOAMAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | NFE2L2 554/4885MAPT 3297/4885MAOA 1902/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | NFE2L2 730/4885MAPT 3512/4885MAOA 3145/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | NFE2L2 730/4885MAPT 3512/4885MAOA 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.